Bimatoprost a review

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 16, 2009, Pages 2759-2768

  Patil, A Jayaprakash ^a,b   Vajaranant, Thasarat S ^b   Edward, Deepak P ^c  

^a SUMMA HEALTH SYSTEM   (United States)

^b NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Bimatoprost; Glaucoma; Intraocular pressure; Ocular hypertension; Prostaglandin; Prostamide

Indexed keywords

ACETAZOLAMIDE; ALPHAGAN P; ANECORTAVE; APRACLONIDINE; BETAXOLOL; BIMATOPROST; BIMATOPROST PLUS TIMOLOL; BRIMONIDINE; BRIMONIDINE PLUS TIMOLOL; BRINZOLAMIDE; BVT 28949; CARBACHOL; CARTEOLOL; DORZOLAMIDE; LATANOPROST; LATANOPROST PLUS TIMOLOL; METHAZOLAMIDE; PF 03187207; PILOCARPINE; PROSTAGLANDIN F2 ALPHA DERIVATIVE; SEROTONIN ANTAGONIST; TAFLUPROST; TIMOLOL; TRAVOPROST; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ALLERGIC CONJUNCTIVITIS; ASTHENIA; ASTHENOPIA; BLEPHARITIS; CATARACT; CHEMOSIS; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; COMBINATION CHEMOTHERAPY; COMMON COLD SYMPTOM; CONJUNCTIVAL HYPEREMIA; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; EPIPHORA; EXFOLIATIVE GLAUCOMA; EYE BURNING; EYE COLOR; EYE DISCHARGE; EYE DISEASE; EYE HYPEREMIA; EYE INFLAMMATION; EYE IRRITATION; EYE PAIN; EYE STINGING; EYELASH; EYELID ERYTHEMA; FOREIGN BODY REACTION; GLAUCOMA; HERPES SIMPLEX KERATITIS; HIRSUTISM; HUMAN; HYPERPIGMENTATION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LIVER FUNCTION TEST; MONOTHERAPY; NONHUMAN; OPEN ANGLE GLAUCOMA; PERIOCULAR PIGMENTATION; PERIORBITAL PIGMENTATION; PHOTOPHOBIA; PIGMENT DISORDER; POSTMARKETING SURVEILLANCE; PRURITUS; PUNCTATE KERATITIS; RETINA MACULA CYSTOID EDEMA; RETINA MACULA EDEMA; REVIEW; SIDE EFFECT; SKIN; UPPER RESPIRATORY TRACT INFECTION; UVEITIC GLAUCOMA; VISUAL DISORDER;

AMIDES; CLOPROSTENOL; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE;

EID: 72949087488     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903292649     Document Type: Review

References (78)

1. Forrester JV, Dick AD, McMenamin PG. The eye: basic sciences in practice, 2nd edition. WB Saunders; Edinburgh; New York: 2002
2. Bill A, Svedbergh B. Scanning electron microscopic studies of the trabecular meshwork and the canal of Schlemm - an attempt to localize the main resistance to outflow of aqueous humor in man. Acta Ophthalmol (Copenh) 1972;503:295-320
3. Grant WM. Clinical measurements of aqueous outflow. AMA Arch Ophthalmol 1951;462:113-131
4. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001;108(11):1943-1953
5. Kahook MY, Noecker R. Quantitative analysis of conjunctival goblet cells after chronic application of topical drops. Adv Ther 2008;258:743-751
6. Kahook MY, Noecker RJ. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea 2008;273:339-343
7. Kahook MY, MT, Williams RD, Edward DP. Histologic analysis of conjunctival samples from patients on chronic intraocular pressure-lowering therapy. Presented at the American Glaucoma Society 19th Annual Meeting 5-8 Mar 2009, San Diego, CA, USA
8. Sutton A, Gouws P, Ropo A. Tafluprost, a new potent prostanoid receptor agonist: a dose-response study on pharmacodynamics and tolerability in healthy volunteers. Int J Clin Pharmacol Ther 2008;468:400-406
9. Stanislaro R. Clinical development initiated on lead compound in NicOx glaucoma collaboration with Pfizer; Pharmaceutical News and Articles, 2007. Available from http://www.drugs.com/ news/clinical-development-initiatedlead- compound-nicox-8217- glaucoma-collaboration-pfizer-5658.html
10. Hanks K. NicOx announces that Pfizer has disclosed further details of glaucoma trial for PF-03187207, in Pharmaceutical news and articles; 2007. Available from http://www.drugs.com/news/nicoxannounces- pfizer-has- disclosedfurther- details-glaucoma-trialpf- 03187207-5668.html
11. Stewart WC, Konstas AG, Nelson LA, Kruft B. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology 2008;1157:1117-1122
12. Robin AL, Suan EP, Sjaarda RN, et al. Reduction of intraocular pressure with anecortave acetate in eyes with ocular steroid injection-related glaucoma. Arch Ophthalmol 2009;1272:173-178
13. Moriuchi H, Koda N, Okuda-Ashitaka E, et al. Molecular characterization of a novel type of prostamide/prostaglandin F synthase, belonging to the thioredoxin-like superfamily. J Biol Chem 2008;2832:792-801
14. Koda N, Tsutsui Y, Niwa H, et al. Synthesis of prostaglandin F ethanolamide by prostaglandin F synthase and identification of Bimatoprost as a potent inhibitor of the enzyme: new enzyme assay method using LC/ESI/MS. Arch Biochem Biophys 2004;4242:128-136
15. Kozak KR, Crews BC, Morrow JD, et al. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem 2002;277:44877-44885
16. Lumigan-Package Insert. A pharmaceuticals, editor. Allergan, Irvine; 2006
17. Krauss AH, Woodward DF. Update on the mechanism of action of bimatoprost: a review and discussion of new evidence. Surv Ophthalmol 2004;49(Suppl 1):S5-11
18. Wan Z, Woodward DF, Cornell CL, et al. Bimatoprost, prostamide activity, and conventional drainage. Invest Ophthalmol Vis Sci 2007;489:4107-4115
19. Woodward DF, Krauss AH, Chen J, et al. The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol 2001;45(Suppl 4):S337-45
20. Gupta V, Srinivasan G, Sharma A, et al. Comparative evaluation of bimatoprost monotherapy in primary chronic angle closure and primary open angle glaucoma eyes: a three-year study. J Ocul Pharmacol Ther 2007;234:351-358
21. Woodward DF, Krauss AH, Wang JW, et al. Identification of an antagonist that selectively blocks the activity of prostamides (prostaglandin- ethanolamides) in the feline iris. Br J Pharmacol 2007;1503:342-352
22. Davies SS, Ju WK, Neufeld AH, et al. Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro. J Ocul Pharmacol Ther 2003;191:45-54
23. Eisenberg DL, Toris CB, Camras CB. Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs. Surv Ophthalmol 2002;47(Suppl 1):S105-15
24. Maxey KM, Johnson JL, LaBrecque J. The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. Surv Ophthalmol 2002;47(Suppl 1):S34-40
25. Hellberg MR, Ke TL, Haggard K, et al. The hydrolysis of the prostaglandin analog prodrug bimatoprost to 17-phenyl-trinor PGF2alpha by human and rabbit ocular tissue. J Ocul Pharmacol Ther 2003;192:97-103
26. Woodward DF, Krauss AH, Chen J, et al. Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024). J Pharmacol Exp Ther 2003;305(2):772-785
27. Van der Valk R, Webers CA, Schouten JS, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 2005;112(7):1177-1185
28. Rossetti L, Karabatsas CH, Topouzis F, et al. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure. Ophthalmology 2007;114(12):2244-2251
29. Christiansen GA, Nau CB, McLaren JW, Johnson DH. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. Ophthalmology 2004;1119:1658-1662
30. Woodward DF, Liang Y, Krauss AH. Prostamides (prostaglandin- ethanolamides) and their pharmacology. Br J Pharmacol 2008;1533:410-419
31. Brubaker RF. Mechanism of action of bimatoprost (Lumigan). Surv Ophthalmol 2001;45(Suppl 4):S347-51
32. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology 1993;1009:1297-1304
33. Cantor LB, Hoop J, Wudunn D, et al. Levels of bimatoprost acid in the aqueous humour after bimatoprost treatment of patients with cataract. Br J Ophthalmol 2007;915:629-632
34. Camras CB, Toris CB, Sjoquist B, et al. Detection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery. Ophthalmology 2004;111(12):2193-2198
35. Dahlin DC, Craven ER, Moster M. Human aqueous humor concentrations of bimatoprost and bimatoprost free acid following topical ocular dosing of lumigan (Bimatoprost (17 phenyl trinor PGF2)) 0.03 % ophthalmic solution (abstract). In The Association for Research in Vision and Ophthalmology. Fort Lauderdale; 2004
36. Camras CB, Sharif NA, Wax MB, et al. Bimatoprost, the prodrug of a prostaglandin analogue. Br J Ophthalmol 2008;926:862-864
37. Noecker RS, Dirks MS, Choplin NT, et al. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003;135(1):55-63
38. Kaufman PL. The prostaglandin wars. Am J Ophthalmol 2003;1364:727-728
39. Parrish RK, Palmberg P, Sheu WP. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003;1355:688-703
40. Gandolfi SA, Cimino L. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmology 2003;1103:609-614
41. Sonty S, Donthamsetti V, Vangipuram G, Ahmad A. Long-term IOP lowering with bimatoprost in open-angle glaucoma patients poorly responsive to latanoprost. J Ocul Pharmacol Ther 2008;245:517-520
42. Williams RD. Efficacy of bimatoprost in glaucoma and ocular hypertension unresponsive to latanoprost. Adv Ther 2002;196:275-281
43. How AC, Kumar RS, Chen YM, et al. A randomised crossover study comparing bimatoprost and latanoprost in subjects with primary angle closure glaucoma. Br J Ophthalmol 2009;936:782-786
44. Konstas AG, Hollo G, Irkec M, et al. Diurnal IOP control with bimatoprost versus latanoprost in exfoliative glaucoma: a crossover, observer-masked, three-centre study. Br J Ophthalmol 2007;916:757-760
45. Fortuna E, Cervantes-Castaneda RA, Bhat P, et al. Flare-up rates with bimatoprost therapy in uveitic glaucoma. Am J Ophthalmol 2008;1466:876-882
46. Scherer WJ. A retrospective review of non-responders to latanoprost. J Ocul Pharmacol Ther 2002;183:287-291
47. Rossetti L. Italian Latanoprost Study Group. Assessment of the rate of non-responders to latnoprost therapy. In ARVO, Fort Lauderdale; 2003
48. Martinez A, Sanchez M. Bimatoprost/timolol fixed combination vs latanoprost/timolol fixed combination in open-angle glaucoma patients. Medscape Ophthalmol 2009;23:810-818
49. Hommer A. A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/ timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. Eur J Ophthalmol 2007;171:53-62
50. Bournias T. Comparison of brimonidine purite, dorzolamide, and brinzolamide as adjunctive therapy to prostaglandin analogs; 2008. Available from http://clinicaltrials.nlm.nih.gov/ ct2/show/NCT00675207? term=brinzolamide&intr=% 22Brimonidine%22&rank=1 [Last accessed 11 Sept 2009]
51. Whitson JT, Netland PA, Hermes E. When and what to add to prostaglandin therapy. Rev Ophthalmol 2005;12:8
52. Robin AL, Lee K, Wogen J, et al. Frequency of adjunctive medication use associated with bimatoprost, travoprost and latanoprost therapy. Presented at the American Glaucoma Society Annual Meeting, 5-8 Mar 2003, San Francisco, CA, USA
53. Laibovitz RA, VanDenburgh AM, Felix C, et al. Comparison of the ocular hypotensive lipid AGN 192024 with timolol: dosing, efficacy, and safety evaluation of a novel compound for glaucoma management. Arch Ophthalmol 2001;1197:994-1010
54. DuBiner H, Cooke D, Dirks M, et al. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol 2001;45(Suppl 4): S353-60
55. Brandt JD, Van Denburgh AM, Chen K, Whitcup SM. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial. Ophthalmology 2001;1086:1023-31; discussion 1032
56. Sherwood M, Brandt J. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol 2001;45(Suppl 4): S361-8
57. Gandolfi S, Simmons ST, Sturm R, et al. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 2001;183:110-121
58. Lee DA, Gross R, Mundorf TK. Lumigan early experience study group: efficacy and safety of bimatoprost 0.03% (lumigan) in a large-scale, open-label clinical trial. In ARVO, Fort Lauderdale; 2002
59. Honrubia F, Garcia-Sanchez J, Polo V, et al. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials. Br J Ophthalmol 2009;933:316-321
60. Kurtz S, Mann O. Incidence of hyperemia associated with bimatoprost treatment in naive subjects and in subjects previously treated with latanoprost. Eur J Ophthalmol 2009;193:400-403
61. Noecker RS, Dirks MS, Choplin N. Comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2004;1371:210-212
62. Astin M, Stjernschantz J, Selen G. Role of nitric oxide in PGF2 alpha-induced ocular hyperemia. Exp Eye Res 1994;594:401-407
63. Easthope SE, Perry CM. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension. Drugs Aging 2002;193:231-248
64. Centofanti M, Oddone F, Chimenti S, et al. Prevention of dermatologic side effects of bimatoprost 0.03% topical therapy. Am J Ophthalmol 2006;1426:1059-1060
65. Kapur R, Osmanovic S, Toyran S, Edward DP. Bimatoprost-induced periocular skin hyperpigmentation: histopathological study. Arch Ophthalmol 2005;12311:1541-1546
66. Doshi M, Edward DP, Osmanovic S. Clinical course of bimatoprost-induced periocular skin changes in Caucasians. Ophthalmology 2006;11311:1961-1967
67. Kothari MT, Mehta BK, Asher NS, Kothari KJ. Recurrence of bilateral herpes simplex virus keratitis following bimatoprost use. Indian J Ophthalmol 2006;541:47-48
68. Kroll DM, Schuman JS. Reactivation of herpes simplex virus keratitis after initiating bimatoprost treatment for glaucoma. Am J Ophthalmol 2002;1333:401-403
69. European Medicines Agency. Lumigan - European Public Assessment Report. EMEA; 2007. Available from http://www.emea.europa.eu/humandocs/ PDFs/EPAR/lumigan/381902en1.pdf [Last accessed Nov 2007]
70. Cantor LB. An update on bimatoprost in glaucoma therapy. Expert Opin Pharmacother 2002;312:1753-1762
71. Cantor LB. Bimatoprost: a member of a new class of agents, the prostamides, for glaucoma management. Expert Opin Investig Drugs 2001;104:721-731
72. Quinones R, Earl ML. The efficacy of bimatoprost 0.03% monotherapy in patients previously using topical beta-blocker monotherapy for the treatment of glaucoma or ocular hypertension. Adv Ther 2004;216:370-379 (Pubitemid 40365905)
73. Quinones R, Severin T, Mundorf T. Efficacy of bimatoprost 0.03 percent in untreated glaucoma and ocular hypertension patients: results from a large community-based clinical trial. J Ocul Pharmacol Ther 2004;202:115-122
74. Goldberg LD, Walt J. Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications. Pharmacoeconomics 2006;243:251-264
75. Walt JG, Lee JT. A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension. Surv Ophthalmol 2004;49(Suppl 1):S36-44
76. Tuil E, Hommer AB, Poulsen PB, et al. The cost-effectiveness of bimatoprost 0.03% in the treatment of glaucoma in adult patients - a European perspective. Int J Clin Pract 2005;599:1011-1016
77. Frenkel RE, Frenkel M, Toler A. Pharmacoeconomic analysis of prostaglandin and prostamide therapy for patients with glaucoma or ocular hypertension. BMC Ophthalmol 2007;7:16
78. Plosker GL, Keam SJ. Bimatoprost: a pharmacoeconomic review of its use in open-angle glaucoma and ocular hypertension. Pharmacoeconomics 2006;243:297-314